参芪扶正联合GP方案化疗治疗晚期NSLC临床对照研究

肖明东

[摘要]目的 通过对比参芪扶正联合GP方案与GP方案分别治疗晚期NSLC的临床效果，探讨参芪扶正联合GP方案对于晚期NSLC治疗效果。 方法 回顾性分析2010年9月～2013年9月间我院收治的60例晚期非小细胞肺癌（NSCLC）患者为研究对象，其中采用参芪扶正联合GP方案化疗者30例（治疗组），单独采用GP方案化疗者30例（对照组）分析比较两组患者的近期临床疗效及其对患者生活质量的影响。 结果 治疗组客观有效率为53.3%，对照组有效率为26.7%，治疗组显著高于对照组（x2=4.4，P=0.03<0.05）；治疗组生活质量提高者比例为50%显著多于对照组16.7%，且差别有统计学意义（x2=7.5，P=0.006<0.05）；治疗组治疗期间发生白细胞下降4例，胃肠道反应7例，血小板下降6例；对照组发生白细胞下降12例，胃肠道反应6例，血小板下降7例。治疗组白细胞下降发生率显著低于对照组（x2=5.6，P=0.02<0.05）。 结论参芪扶正联合GP方案治疗晚期NSCLC可显著提高临床疗效，降低白细胞下降不良反应发生风险。

[关键词]参芪扶正注射液；GP方案；非小细胞肺癌

[中图分类号]R734.2 [文献标识码]B [文章编号]2095-0616（2014）20-173-03

Shenqifuzheng combined with GP in the treatment of non-small cell lung carcinoma

XIAO Mingdong

Department of Pharmacy，the Peoples Hospital of Aletai Area，Aletai 836500，China

[Abstract]Objective The aim of this study was to evaluate the clinical efficacy of shenqifuzheng combined with GP regimen in the treatment of non-small cell lung carcinoma. Methods 60 cases with NSCLC was retrospectively analyzed in our hospital from 2010 to 2013.Of the included 60 cases，30 patients were treated with GP+Shenqifuzheng and other 30 cases were treated with GP chemotherapy only.The clinical efficacy，life quality improvement and side effects were compared between the two groups. Results The objective response rate was 53.3% and 26.7% in the treatment and control group respectively，with statistical difference between the two groups（x2=4.44，P=0.03<0.05）；The life quality improvement in the treatment was much higher than that of control group（x2=7.5，P=0.006<0.05）；The granulocytopenia risk in treatment group was much lower than that of control group（x2=5.6，P=0.02<0.05）. Conclusion Shenqifuzheng combined with GP regimen chemotherapy can significant improve the clinical efficacy and decrease the risk of side effects in patients with non-small cell lung cancer.

[Key words]Shenqifuzheng；GP regimen；Non-small cell lung carcinoma

近年来肺癌发生率出现明显上升趋势，根据病理学及肺癌生物学行为，肺癌主要分为非小细胞肺癌（NSCLC）和小细胞肺癌，其中NSCLC约占整个肺癌发病率的80%[1-2]。NSCLC患者早期发病隐匿，诊断明确时已大多发展为晚期，失去手术时机，往往需采用化疗。但近年来以顺铂为基础的联合第三代化疗药物的一线化疗方案如GP、NP及DP等有效率并无明显差别。但不良反应发生率均较高，因此提高化疗疗效的同时降低化疗不良反应，提高患者生活治疗是目前肺癌化疗的研究热点。随着中医药技术的不断发展，中药在提高癌症患者的机体的免疫力，减轻不良症状反应，提高患者体质和日常生活质量方面取得了可喜的成绩[3-4]。中药调理联合化疗治疗为治疗中晚期癌症，减轻他们的不良症状反应开辟了新的途径。本研究就参芪扶正联合GP疗法治疗NSLC的研究结果，报道如下。……